FDA To Reassess Avandia Risk After Revisited Study
The U.S. Food and Drug Administration announced Friday it would consider another regulatory review of GlaxoSmithKline PLC's former blockbuster diabetes treatment Avandia, which is restricted over cardiovascular risks, following a re-examination...To view the full article, register now.
Already a subscriber? Click here to view full article